InsiderTrades

Form 4 for CRSP CRISPR Therapeutics AG

Accepted 2025-10-15 00:00:00 ET · period of report 2025-10-13 · accession 0001193125-25-240437 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2025-10-15 2025-10-14 CRSP KASINGER JAMES R. GC, Sec S - Sale+OE $66.60 -1,076 83.4K -1% -$71.7K
D 2025-10-15 2025-10-13 CRSP KASINGER JAMES R. GC, Sec M - OptEx — +2,114 84.5K +3% —
D 2025-10-15 2025-10-13 CRSP KASINGER JAMES R. GC, Sec M - OptEx — -2,114 2,113 -50% —

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Shares 2025-10-14 S D 1,076 $66.60 83,402 D — — (F3) Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
2 Common Common Shares 2025-10-13 M A 2,114 — 84,478 D — — (F1) Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. (F2) Includes 635 shares acquired under the CRISPR Therapeutics AG 2016 Employee Stock Purchase Plan.
3 Derivative Restricted Stock Units 2025-10-13 M D 2,114 — 2,113 D — · — to — 2,114 Common Shares (F1) Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. (F4) This restricted stock unit award was granted on October 13, 2023 with respect to 6,340 Common Shares, with (i) one third of the shares vesting on October 13, 2024, (ii) one third of the shares vesting on October 13, 2025, and (iii) one third of the shares vesting on October 13, 2026.